Abstract:Data sources Four electronic databases, namely PubMed, Scopus, Web of Science and the Cochrane Central Register of Controlled Trials, were searched from their inception to 16 July 2019. The OpenGrey database was also used to identify unpublished studies.Study selection Eligible study designs included randomised controlled trials, cohort studies, case-control studies and case series with a retrospective, cross-sectional or prospective design related to implant placement in patients with a history of anti-angiogenic or antiresorptive medications. Selection was conducted by two independent reviewers; however, if a consensus was not reached, a third reviewer was involved. Studies required a minimum of five patients with a history of antiresorptive or anti-angiogenic drug therapy before implant placement and strict criteria were used to ensure studies reported sufficient data items for discussion. Only full papers in the English language were included.Data extraction and synthesis A total of 6,073 papers were initially identified following removal of duplicates and 29 of these met the inclusion criteria for this systematic review. Twenty-eight reported on bisphosphonates which included five cohort studies, six case-control studies and 17 case series. A single case series reported on denosumab and no studies were identified reporting on selective oestrogen receptor modulators, calcitonin or anti-angiogenics. The quality of the included cohort and case-control studies were assessed by applying the modified Newcastle-Ottawa scale while the case series were assessed according to the Joanna Briggs Institute critical appraisal checklist. A score of <50% was considered to indicate low quality, 50-70% moderate quality and >75% high quality. A standardised Microsoft Excel spreadsheet was used to extract data from the studies which included study design, number of cases, implants and controls, patient characteristics (systemic diseases/age/gender/smoking status), drug history (type of drug, indication, administration route, intake before implant placement), whether patients were taking the drug at the time of implant placement and follow-up, reported outcome and parameters (implant loss, failure, success, survival and incidence of medication-related osteonecrosis of the jaw [MRONJ]). Where data was missing, estimations were calculated and a qualitative synthesis of all data was performed.Results No single study reported all the relevant data required by the authors and the overall level of quality was moderate. Regarding implant failure, patients with a history of bisphosphonates for osteoporosis are not at increased risk. However, insufficient data was available for those with a history of bisphosphonates for cancer, or any other antiresorptive or anti-angiogenic medications. Comparing this to MRONJ, patients with a history of bisphosphonate treatment are at risk of developing MRONJ following implant placement, while those with a history of denosumab for osteoporosis have a negligible risk. There was insufficient data available to assess the risk of MRONJ for those with a history of denosumab for cancer or other antiresorptive or anti-angiogenic medications.Conclusions Patients with a history of bisphosphonate treatment are at risk of MRONJ following implant placement while patients who take bisphosphonates for osteoporosis are not at increased risk of implant failure. There is a negligible risk of developing MRONJ in those taking denosumab for osteoporosis. However, practitioners should bear in mind a lack of high-quality evidence regarding the safety of placing implants in patients with a history of antiresorptive or anti-angiogenic medications.

No increased risk of osteonecrosis of the jaw in osteoporotic patients with dental implants: a nationwide cohort study

Pulp and periapical disease as a risk factor for osteonecrosis of the jaw: a national cohort-based study in Korea

Clinical and Radiographic Features of Peri‐Implant Medication‐Related Osteonecrosis of the Jaw: A Retrospective Study

A Retrospective Study of 30,959 Implants: Risk Factors Associated with Early and Late Implant Loss

Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients

Effect of anti-resorptive therapy on implant failure: a systematic review and meta-analysis

Is it safe to place implants in patients at risk of MRONJ?

Analysis of the relationship between periodontitis and osteoporosis/fractures: a cross-sectional study

Dental Implant Failure in Post-Menopausal Women on Oral Bisphosphonates: A Systematic Review and Meta-Analysis

A study of peri-implant tissue clinical parameters in patients starting anti-osteoporosis medication after existing implant function: a prospective cohort study

Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database

Bisphosphonate-Associated Osteonecrosis Of The Jaw In Oncology Patient: Case Report.

Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review

Risk Factors Influencing Medication‐Related Osteonecrosis of the Jaws (MRONJ) Following Dental Extraction Among Osteoporotic Patients in Taiwan

Is immediate dental implant in fibula free flap beneficial for implant survival and osteoradionecrosis in jaw reconstruction?

Effect of osteopenia and osteoporosis on failure of first and second dental implants: a retrospective observational study

Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study

Can medication-related osteonecrosis of the jaw be attributed to specific microorganisms through oral microbiota analyses? A preliminary study

The Occurrence of Alzheimer's Disease and Parkinson's Disease in Individuals With Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Screening Database in Korea

Impact of antiresorptive agents on mortality risk in postmenopausal women with osteoporosis: insights from a nationwide cohort study